Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million ...
The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
Medtronic (MDT) recently announced that it has received a favorable decision with respect to a long-standing patent dispute related to sacral neuromodulation. Specifically, per Medtronic’s press ...
Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...
Axonics Modulation Technologies has received premarket approval from the Food and Drug Administration (FDA) for Axonics r-SNM System, an implantable sacral neuromodulation device (SMN), for the ...
This x-ray of the pelvis shows an electronic nerve-stimulating device in the right iliac fossa. Over 10 months, complete continence was achieved by approximately half of implanted patients. Real-world ...
US Medical device giant Axonics has announced that it has secured market clearance from Australia’s Therapeutic Goods Administration (TGA) for its R20 rechargeable sacral neuromodulation (SNM) system ...
Follow-up of patients at a Belgian institution reveals that sacral neuromodulation (SNM) is effective for the treatment of lower urinary tract dysfunction (LUTD) over the long term, but often requires ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results